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In the previous issue of Critical Care, Wang and 
colleagues [1] present interesting data from a large cohort 
of unselected medical intensive care unit (ICU) patients 
which examined the prognostic utility of two well-
established biomarkers: N-terminal pro-brain natriuretic 
peptide (NT-proBNP) and C-reactive protein (CRP). In 
fact, the authors’ observations nicely complement the 
picture that is emerging from several recent studies 
[1-14]. Like most of the previous studies, their ﬁ  ndings 
leave the majority of ICU physicians in doubt about 
whether biomarkers are utile or futile.
Th  e ICU is a rather hostile setting for biomarkers. 
Biomarkers complement other clinical information by 
proving quantitative data regarding a pathophysiological 
mechanism that can be used for the early diagnosis of a 
speciﬁ  c disease, to monitor and guide treatment, and to 
predict the risk of death or other adverse events. Th  e 
stronger the link between the information provided by 
the biomarker and the immediate clinical course of 
action that we physicians take in response, the higher the 
clinical utility of the biomarker [13,14].
In most patients ﬁ  nally being admitted to an ICU, the 
diagnosis is made prior to ICU admission, most 
commonly in the emergency department (ED). Of course, 
we still face diagnostic uncertainty in many patients who 
develop new symptoms or signs during their stay in the 
ICU (for example, respiratory deterioration or fever). To 
appropriately examine the diagnostic accuracy of a 
biomarker in these settings, we need to deﬁ  ne a gold 
standard diagnosis against which the blinded biomarker 
results are then compared. Unfortunately, owing to, for 
example, the low speciﬁ  city of chest x-ray ﬁ  ndings, the 
adjudication of a ﬁ  nal diagnosis often is challenging for 
many common ICU disorders, such as ventilator-
associated pneumonia and hypoxemic respiratory failure 
[7,10,12]. In addition, the extent to which experience and 
diag nostic  cutoﬀ   levels can be transferred from studies 
per  formed in the ED to the critically ill patients in the 
ICU is questionable [7,10-14]. Major diﬀ  erences  in 
patient characteristics, disease severity, comorbidity, 
resources available for the individual patient, and 
therapies applied between the ICU and the ED require 
that the potential clinical use of biomarkers in the ICU be 
deﬁ  ned by speciﬁ  c ICU studies.
What about the utility of biomarkers in monitoring 
treatment? Biomarkers are used routinely to monitor the 
eﬃ     cacy and safety of treatment. For example, urine 
output and serum creatinine are used to quantify renal 
function; tidal volumes, oxygen saturation, and arterial 
partial pressure of oxygen [PaO2] are used to tailor 
ventilator settings; and body temperature, CRP, and pro-
calcitonin are used to assess the response to anti  biotics. 
Although the use of biomarkers in many of these indica-
tions is mainly empirical and only partly supported by 
large prospective studies, it is perceived by most clini-
cians as utile as the links between the biomarker infor-
mation and therapeutic consequences are strong [11].
Th   e case is more challenging for prognostic biomarkers. 
Th  e link to a speciﬁ   c consequence is weakest for 
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© 2011 BioMed Central Ltdprog  nostic biomarkers applied in patients with a wide 
variety of diseases, such as in unselected ICU patients. 
Th   e added value of most, if not all, previously examined 
biomarkers on top of current ICU mortality scores seems 
to be too low to justify clinical use [1-6]. Th  e  prognostic 
accuracy for ICU or in-hospital death of most biomarkers 
is modest and inferior to that provided by, for example, 
the APACHE (Acute Physiology and Chronic Health 
Evaluation) score [1-7]. Th   is observation seems to be well 
explained by the wide range of disorders leading to ICU 
admission and the fact that diﬀ  erent organ systems may 
be the most severely damaged and therefore critical for 
survival. Moreover, it is important to highlight that there 
is no perceived unmet clinical need to appropriately risk-
stratify most patients in the ICU. Simple clinical 
variables, many of which are captured in the ICU scores, 
provide immediate and reasonable risk prediction. As 
cardiovascular function is the key variable in many 
critically ill patients, BNP and NT-proBNP – as 
quantitative markers of hemodynamic cardiac stress and 
heart failure summarizing the extent of systolic and 
diastolic left ventricular dysfunction, valvular dys-
function, and right ventricular dysfunction – have been 
shown to be predictors of death in several previous 
studies. We are still searching how to best apply this 
information in the clinical care of critically ill patients.
However, prognostic biomarker studies, particularly 
with BNP and NT-proBNP, have already contributed to a 
better understanding of many disorders in the ICU. In 
fact, the observation that hemodynamic cardiac stress is 
present in multiple conditions provided important novel 
insights into pathophysiology and highlighted a dominant 
role of the cardiovascular system of many common 
disorders in the ICU, including septic shock and weaning 
failure [8,9,12]. Ultimately, these insights will contribute 
to improvements in our management of ICU patients.
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